FDA Approves Genentech ’s Tecentriq in Combination With Avastin for People With Hepatocellular Carcinoma

South San Francisco, CA -- May 29, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq ® (atezolizumab) in combination...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news